Successful treatment of X-linked lymphoproliferative disease (XLP) with anti-CD20 monoclonal antibody (Rituximab) followed by mismatched unrelated cord blood transplantation

T. L. Lee, Ka Wai Helen Law, G. C.F. Chan, S. Y. Ha, M. H.K. Ho, K. W. Chan, Y. L. Lau

Research output: Journal article publicationJournal articleAcademic researchpeer-review

5 Citations (Scopus)


A 4-year-old boy with X-linked lymphoproliferative disease (XLP) developed life-threatening acute lymphoproliferative crisis and failed to respond to conventional treatment of dexamethasone and etoposide. With the knowledge that uncontrolled alloreactive cytotoxic T-cell responses triggered by EBV-transformed B cells is the main cause of XLP, anti-CD20 monoclonocal antibody (Rituximab) which directed against B lymphocytes was use to damp down the patient's dysregulated immune response. He responded well to this novel approach and entered into complete remission with this treatment. His inherited immuno-deficient genetic defect was subsequently corrected by unrelated cord blood transplantation.
Original languageEnglish
JournalHong Kong Journal of Paediatrics
Issue number3
Publication statusPublished - 1 Jul 2006
Externally publishedYes


  • Anti-CD20 monoclonal antibody
  • Cord blood transplantation
  • Rituximab
  • X-linked lymphoproliferative disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this